KPV is a three-amino-acid fragment of alpha-MSH studied for its role in inflammatory signaling and epithelial-barrier research. Explore KPV from Amino Club. Use code NOW20 for 20% off bit.ly/amino_club Research use only.

Retatrutide keeps pulling attention across X. The reason is simple: one investigational molecule targets GLP-1, GIP and glucagon receptors. Three pathways. One very active research conversation.

A peptide is defined by its amino-acid sequence—not by one shared function. Some act as signals. Others influence structure, metabolism or immune pathways. One broad compound class. Very different biology.

Semaglutide, tesamorelin and ipamorelin are all peptides. But that label tells you surprisingly little about how they work. To understand the differences, follow the receptor. SEMAGLUTIDE → GLP-1 RECEPTOR This pathway is involved in appetite and glucose regulation. Semaglutide can reduce hunger and food intake, while supporting glucose-dependent insulin secretion. That connects its mechanism to the outcomes people recognize from its metabolic research: changes in blood glucose, body weight and body composition. TESAMORELIN → GHRH RECEPTOR Tesamorelin stimulates the pituitary to release growth hormone through the growth hormone-releasing hormone pathway. Its pivotal trials examined excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Researchers measured a specific fat compartment—not simply the number on the scale. IPAMORELIN → GHRELIN RECEPTOR Ipamorelin stimulates GH release through the ghrelin receptor pathway. That puts it in the same broad GH conversation as tesamorelin, but the signal enters through a different receptor. Sharing a hormonal endpoint does not make two compounds interchangeable. This is why “which peptide is better?” needs a more specific question. Better for which biological target? Which measured outcome? In which population? Appetite regulation and GH signaling are different starting points. Even within the GH axis, the receptor and compound matter. Once those distinctions are clear, peptide research becomes much easier to navigate—and comparisons become far more useful than a list of overlapping benefit claims.

GHK-Cu is getting plenty of attention across X—and the mechanism is why. This copper-binding tripeptide is studied in collagen synthesis, skin remodeling and tissue-repair signaling. Amino Club | Code NOW20 for 20% off 🔗 bit.ly/amino_club For research purposes.

Can GLP-1-based therapies help people with heart failure? For obesity-related HFpEF, clinical trials offer encouraging results. HFpEF means the heart’s pumping fraction remains preserved, but filling is impaired. Breathlessness, fatigue and reduced exercise capacity can make everyday activities difficult. Four trials help explain where the evidence stands: • STEP-HFpEF — semaglutide improved symptoms, physical limitations, walking performance and weight in people with HFpEF and obesity, without diabetes. • STEP-HFpEF DM — similar benefits were observed in people who also had type 2 diabetes. • SUMMIT — tirzepatide lowered the relative risk of cardiovascular death or worsening heart failure by 38%. The benefit was driven mainly by fewer worsening heart failure events. • SELECT — a broader cardiovascular trial in people with established cardiovascular disease and overweight or obesity. Only 12.9% had HFpEF at baseline; HFpEF was not required for enrollment. These studies answer different questions: how people feel, what they can do and whether serious events occur. Together, they show why the conversation around metabolic therapies now includes heart failure symptoms, daily function and clinical outcomes. The clearest interpretation starts with who was studied and what was measured.